Pepti · Catalog · BB10 / BPC-157 + TB-500
BB10-style blend · BPC-157 + TB-500
A BB10-style co-lyophilized research peptide blend of BPC-157 and TB-500 for qualified B2B buyers. ≥99% HPLC purity target with batch-linked COA, HPLC chromatogram and MS identity record. Reply ≤4h.
Vial illustrations reflect supplied lyophilized format. Production lots carry their own batch references and document pack.
| Compound | BB10-style BPC-157 + TB-500 blend |
|---|---|
| Common search name | BB10 / BB 10 peptide blend (buyer shorthand) |
| Sequence | Confirmed on batch-linked COA for each production lot |
| Molecular weight | Components confirmed on COA |
| Form | Lyophilized powder, glass vial |
| Purity target | ≥ 99% by HPLC |
| Vial formats | 5 mg + 5 mg, 10 mg + 10 mg |
| Documentation | Batch-linked COA + HPLC chromatogram + MS identity record for every production lot |
| Storage | 2–8 °C protected from light; long-term −20 °C |
| Tier | Quantity | Lead time |
|---|---|---|
| Sample lot | From 1 kit (10 vials) | Quoted after RFQ, stock and document review |
| Production lot | RFQ-based, often 200–1,000 vials | Quoted by formula, packaging and document scope |
| OEM repeat | 1,000+ vials | 14–18 days, scheduled |
Pricing is tier-based and quoted per inquiry. Add BB10 / BPC-157 + TB-500 to the Quote Cart for a reply within 4 business hours.
Research blend overview
Pepti manufactures BB10-style BPC-157 + TB-500 as a research-use lyophilized blend for qualified B2B procurement. The format keeps both components in the same vial and the same production record, so purchasing, QC review and repeat supply can be managed against one lot file instead of two unrelated single-peptide lots.
The common BB10 shorthand usually refers to a 1:1 BPC-157 + TB-500 blend, most often 5 mg + 5 mg per vial. Pepti can also quote 10 mg + 10 mg vial formats where the project and documentation scope support them.
BPC-157 is a synthetic 15-amino-acid peptide, commonly referenced in published preclinical literature under CAS 137525-51-0. Research discussions often focus on angiogenesis signaling, nitric-oxide pathway modulation and tendon, ligament or gastrointestinal tissue models. Pepti treats it as a research raw material only.
TB-500 is commonly associated with Thymosin Beta-4 research, CAS 885340-08-9, a 43-amino-acid peptide family studied for actin binding, cell migration, endothelial signaling and tissue-remodeling models. Identity is confirmed at the component level in the lot document set.
Combination rationale
Published preclinical research describes BPC-157 and Thymosin Beta-4/TB-500 through different, partly overlapping repair-biology pathways. Buyers sourcing a 1:1 blend are usually trying to standardize a two-component reference material for laboratory models, not to replace scientific validation or local regulatory review.
Co-lyophilized supply reduces the procurement risk of mixing two unrelated lots after purchase. The BPC-157 and TB-500 contributions are reviewed together under one finished-lot record.
BPC-157 is often discussed around VEGF/NO-related signaling and early repair models, while TB-500/Thymosin Beta-4 literature emphasizes actin-cytoskeleton biology, migration and remodeling models.
Pepti supplies this material for B2B research procurement only and does not provide medical or administration guidance. Buyer teams are responsible for lawful handling, import review and use-case qualification.
Documentation
Pepti's current commitment is batch-linked COA + HPLC chromatogram + MS identity record for every production lot. Independent third-party testing can be arranged when a buyer needs an additional verification path before scaling.
Purity is reviewed for the BPC-157 and TB-500 components, with chromatogram evidence and resolved peak discussion where applicable. We avoid generic or unrelated COA files for active RFQs.
Mass spectrometry identity records support the stated component identities against the BPC-157 and TB-500 mass profiles.
Lot code is reflected in the document pack. COA preview, chromatogram, MS record, water content and packaging documents are confirmed by current stock or production RFQ.
FAQ
A BB10-style co-lyophilized research blend of BPC-157 and TB-500. It ships as a lyophilized powder in a glass vial with a batch Certificate of Analysis (for the production lot). For research and B2B use only.
Eligible sample path starts from 1 kit (10 vials). Production pricing and lead time depend on RFQ details, current batch availability, packaging scope and destination.
Every production lot includes a batch-linked COA, HPLC chromatogram and MS identity record, with lot traceability. Buyers can review batch documents and use independent testing before scaling.
Yes — neutral or branded vial labels, carton design, document packs and lot-code handling for repeat OEM supply. See the OEM service path.
They keep the same 1:1 component concept while changing the per-vial material amount: 5 mg + 5 mg or 10 mg + 10 mg. Pepti confirms available format, batch documents and quote terms before invoicing.
No. Pepti supplies B2B research materials and lot documentation only. We do not provide medical, administration or reconstitution guidance.
Related compounds